Sembayev D 1

1. Assessment of safety and tolerability of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: Results of an open-label, randomized, multicenter, phase IIIB ESCAPE trial
2. Audit efficiency and influence of environmental factors to state bodies: Evidence of kazakhstan doi: Https://doi.org/10.14505/jemt.v8.3(19).01
1